Study of high density lipoprotein cholesterol (HDL-C)-raising mechanism of rosuvastatin (CRESTOR™) by quantifying the key steps of reverse cholesterol transport (RCT)
Study identifier:4522AS/0003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A randomised, double-blind, placebo-controlled, crossover pilot study to define the high density lipoprotein cholesterol (HDL-C)-raising mechanism of rosuvastatin (CRESTOR™) by quantifying the key steps of reverse cholesterol transport (RCT)
Medical condition
Metabolic Syndrome
Phase
Phase 3
Healthy volunteers
No
Study drug
Rosuvastatin
Sex
Male
Actual Enrollment
15
Study type
Interventional
Age
45 Years - 65 Years
Date
Study Start Date: 01 Aug 2003
Primary Completion Date: 01 Nov 2004
Study Completion Date: 01 Dec 2004
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Paul J Nestel
Baker Heart Research Institute
